On a day filled with individual biotech stocks suffering large plunges, Esperion Therapeutics Inc ESPR was one of the bigger movers, falling 40 percent. Esperion gave a regulatory update for ETC-1002. The FDA didn't sign off on lowering of LDL-C as an acceptable regulatory endpoint for approval for treatment of stating-intolerant patients.
JPMorgan wrote in a note that they viewed the news as a overhang in the U.S. as the FDA may still want class-by-class outcomes after the initial approval of LDL-C as a surrogate endpoint. However, JPMorgan noted Esperion may have a path forward with the EMA, as the MAA filing will be judged based on Phase 3 LDL-C lowering efficacy studies starting this year.
Despite this small silver lining, the sell-side firm downgraded Esperion from Overweight to Neutral, while drastically cutting price target from $50 to $15 per share.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.